Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Tumors × Capecitabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 39 Pancreatic Neoplasms 29 Rectal Neoplasms 28 Colorectal Neoplasms 28 Neoplasms 25 Stomach Neoplasms 19 Neoplasm Metastasis 14 Colonic Neoplasms 12 Unspecified Adult Solid Tumor, Protocol Specific 11 Esophageal Neoplasms 9 Carcinoma, Non-Small-Cell Lung 9 Solid Tumor 7 Biliary Tract Neoplasms 7 Carcinoma, Hepatocellular 4 Bile Duct Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Prostatic Neoplasms 3 Ovarian Neoplasms 3 Liver Neoplasms 3 Head and Neck Neoplasms 3 Gallbladder Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Appendiceal Neoplasms 3 Anus Neoplasms 3 Vaginal Neoplasms 2 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Neoplasms, Unknown Primary 2

Interventions

toripalimab 1 camrelizumab 1 Radiotherapy 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03781362 2022-07-20

Study of CPI-100 in Patients With Advanced Tumors

Coordination Pharmaceuticals, Inc.

Phase 1 Completed

Advanced Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡